Jan 25, 2018 7:30am EST ProMIS Neurosciences Issues White Paper Entitled: "Not All Amyloid Beta Therapeutics Are Created Equal"
Jan 23, 2018 7:30am EST ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
Jan 04, 2018 7:30am EST ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies
Oct 17, 2017 7:30am EDT ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease
Sep 28, 2017 7:30am EDT ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference
Sep 19, 2017 7:30am EDT ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer's Disease